Investor Relations

Corporate ProfileNuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge, neural-interface technologies for the neuroscience pre-clinical research market.

On March 14, 2016, Nuvectra Corporation completed its spin-off from Greatbatch, Inc. into an independent, publicly-traded neurostimulation medical device company. The company is headquartered in Plano, Texas, with additional locations in Denver, Ann Arbor, and Minneapolis.

Nuvectra currently trades on the NASDAQ Global Market (NASDAQ) under the ticker symbol "NVTR."


Stock Quote NVTR (Common Stock) $10.81 - 0.41 (3.65%)
ExchangeNASDAQ
Volume44,924
Today's Open$11.17
Previous Close$11.22
Data as of 08/23/17 4:00 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: NVTR.O.  Currently trading at $10.81 with a 52 week high of $15.00 and a 52 week low of $4.63.

Recent News

August 08, 2017

Nuvectra™ Reports Second Quarter 2017 Financial Results

Record Quarterly Algovita® Revenues, Increasing 62% Sequentially PLANO, Texas, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, today announced financial results for the second quarter ended June 30, 2017. Highlights Record consolidated revenues of $7.2 million, including total Algovita® sales of $5.5 million Completed FDA regulatory submission for full-body MRI-conditional approval for the Algovita SCS system On tr

Read More >

July 28, 2017

Nuvectra to Present at the Wedbush PacGrow Healthcare Conference

PLANO, Texas, July 28, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at the Wedbush PacGrow Healthcare Conference in New York, NY. Management will also be available for one-on-one meetings at the conference. Event:       Wedbush PacGrow Healthcare Conference Format:     Present

Read More >


Investor Contact

The Ruth Group
Brian Johnston
Zack Kubow
investors@nuvectramed.com

Events
There are currently no events scheduled.